2024
Pharmacological Interventions for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Tourette Disorder: A Systematic Review and Network Meta-Analysis
Farhat L, Behling E, Landeros-Weisenberger A, de Barros P, Polanczyk G, Cortese S, Bloch M. Pharmacological Interventions for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Tourette Disorder: A Systematic Review and Network Meta-Analysis. Journal Of Child And Adolescent Psychopharmacology 2024 PMID: 39320340, DOI: 10.1089/cap.2024.0049.Peer-Reviewed Original ResearchADHD symptomsAttention-deficit/hyperactivity disorderTic severityTourette's disorderAttention-deficit/hyperactivityRandomized controlled trialsA2 agonistPharmacological interventionsADHD symptom severityIncreased tic severityPersistent tic disordersNetwork meta-analysisStandardized mean differencePairs of medicationsEfficacy of pharmacological interventionsWorsen ticsRandom-effects network meta-analysisSymptom severityTic disordersADHDMeta-analysisNetwork meta-analysis frameworkCertainty of evidenceDisordersNetwork meta-analyses
2023
Editorial: Developmental considerations in addressing the earlier age of severe eating disorder onset
Kamody R, Bloch M. Editorial: Developmental considerations in addressing the earlier age of severe eating disorder onset. Journal Of Child Psychology And Psychiatry 2023, 64: 1101-1103. PMID: 37408467, DOI: 10.1111/jcpp.13852.Peer-Reviewed Original ResearchConceptsMental health concernsHealth concernYouth mental health careMental health careCOVID-19 pandemicImpact of ageYouth mental healthSevere presentationPediatric hospitalizationsDisorder onsetAge of childrenDisorder presentationsMental healthHealth careHospitalizationAgeEarly ageCareDisordersDevelopmental considerationsOnsetPresentationPandemicDeleterious impactThe genetic epidemiology of obsessive-compulsive disorder: a systematic review and meta-analysis
Blanco-Vieira T, Radua J, Marcelino L, Bloch M, Mataix-Cols D, do Rosário M. The genetic epidemiology of obsessive-compulsive disorder: a systematic review and meta-analysis. Translational Psychiatry 2023, 13: 230. PMID: 37380645, PMCID: PMC10307810, DOI: 10.1038/s41398-023-02433-2.Peer-Reviewed Original ResearchConceptsFirst-degree relativesSystematic reviewPopulation-based studyGenetic epidemiologyRelatives of childrenOutcomes of interestFirst systematic reviewObsessive-compulsive disorderRecurrence rateFamilial recurrence rateMedical recordsOpenGrey databasesControl groupControl probandsFamilial disorderAdolescent probandsStudy designEpidemiologyTwin study designOCD diagnosisIndependent researchersDizygotic twinsTwin pairsDisordersOCDPrevalence and gender distribution of excoriation (skin-picking) disorder: A systematic review and meta-analysis
Farhat L, Reid M, Bloch M, Olfson E. Prevalence and gender distribution of excoriation (skin-picking) disorder: A systematic review and meta-analysis. Journal Of Psychiatric Research 2023, 161: 412-418. PMID: 37023597, PMCID: PMC11137851, DOI: 10.1016/j.jpsychires.2023.03.034.Peer-Reviewed Original ResearchConceptsExcoriation disorderPublic health impactEpidemiological studiesGeneral populationSystematic reviewHealth impactsDifferent prevalence estimatesPooled prevalenceOverall prevalenceInclusion criteriaMale ratioPubMed searchPrevalence estimatesGender distributionDisordersPrevalenceDatabase searchEMBASEReviewPopulationPubMedPsycINFOStudyWomenCharacteristics of trichotillomania and excoriation disorder across the lifespan
Lin A, Farhat L, Flores J, Levine J, Fernandez T, Bloch M, Olfson E. Characteristics of trichotillomania and excoriation disorder across the lifespan. Psychiatry Research 2023, 322: 115120. PMID: 36842397, PMCID: PMC10023474, DOI: 10.1016/j.psychres.2023.115120.Peer-Reviewed Original ResearchConceptsExcoriation disorderClinical characteristicsSkin-picking severityAttention-deficit/hyperactivity disorderCo-occurring conditionsBody-focused repetitive behaviorsObsessive-compulsive disorderSeverity scoreCurrent symptomsSignificant positive correlationTrichotillomaniaHyperactivity disorderDisordersSelf-reported anxietyAge 4High rateSubtypesSelf-report measuresSeverityCross-sectional survey responsesRepetitive behaviorsAdulthoodPositive correlation
2022
Parental age and the risk of bipolar disorder in the offspring: A systematic review and meta‐analysis
Polga N, de Barros P, Farhat LC, de Almeida K, Bloch MH, Lafer B. Parental age and the risk of bipolar disorder in the offspring: A systematic review and meta‐analysis. Acta Psychiatrica Scandinavica 2022, 145: 568-577. PMID: 35188977, DOI: 10.1111/acps.13418.Peer-Reviewed Original ResearchConceptsRisk of BDBipolar disorderMaternal ageOdds ratioParental ageReference categoryOlder maternal age groupsAge groupsPaternal age groupsMaternal age groupsWeb of ScienceObservational studySystematic reviewAgeFurther studiesRiskDisordersOffspringAssociationEffect size indexEMBASEGroupSize indexPubMedStudy
2021
Systematic Review and Meta-analysis: An Empirical Approach to Defining Treatment Response and Remission in Pediatric Obsessive-Compulsive Disorder
Farhat LC, Vattimo EFQ, Ramakrishnan D, Levine JLS, Johnson JA, Artukoglu BB, Landeros-Weisenberger A, Asbahr FR, Cepeda SL, Comer JS, Fatori D, Franklin ME, Freeman JB, Geller DA, Grant PJ, Goodman WK, Heyman I, Ivarsson T, Lenhard F, Lewin AB, Li F, Merlo LJ, Mohsenabadi H, Peris TS, Piacentini J, Rosa-Alcázar AI, Rosa-Alcázar À, Rozenman M, Sapyta JJ, Serlachius E, Shabani MJ, Shavitt RG, Small BJ, Skarphedinsson G, Swedo SE, Thomsen PH, Turner C, Weidle B, Miguel EC, Storch EA, Mataix-Cols D, Bloch MH. Systematic Review and Meta-analysis: An Empirical Approach to Defining Treatment Response and Remission in Pediatric Obsessive-Compulsive Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry 2021, 61: 495-507. PMID: 34597773, DOI: 10.1016/j.jaac.2021.05.027.Peer-Reviewed Original ResearchConceptsPediatric obsessive-compulsive disorderObsessive-compulsive disorderOptimal cutoffYale-Brown ObsessiveCY-BOCSClinical trialsSystematic reviewClinical Global Impression-ImprovementRandom-effects meta-analysis modelDiscriminative abilityStandardized operational definitionsMeta-analysis modelChildren's Yale-Brown ObsessiveDiagnostic test accuracyTreatment responseRemissionSeverity ScaleMeta-AnalysisYouden indexCompulsive ScaleTrialsDisordersMeta-Analysis: Pediatric Placebo Response in Depression Trials Does Not Replicate in Anxiety and Obsessive-Compulsive Disorder Trials
Nasir M, Li F, Courley S, Olten B, Bloch MH. Meta-Analysis: Pediatric Placebo Response in Depression Trials Does Not Replicate in Anxiety and Obsessive-Compulsive Disorder Trials. Journal Of Child And Adolescent Psychopharmacology 2021, 31: 670-684. PMID: 34558984, DOI: 10.1089/cap.2021.0030.Peer-Reviewed Original ResearchConceptsPlacebo response ratesObsessive-compulsive disorderPlacebo responseDepression trialsResponse ratePlacebo improvementSymptom improvementAntidepressant trialsStratified subgroup analysisRandom-effects modelPediatric populationSubgroup analysisStudy visitNumber of subjectsPsychopharmacological trialsPubMed searchDifferent indicationsDiagnostic indicationsMean differenceAnxiety disordersTrialsDisordersPediatric anxietyPredictorsPossible correlates
2020
Chapter 39 Obsessive–compulsive disorder
Bloch M, Artukoglu B, Lennington J, Szuhay G, Lombroso P. Chapter 39 Obsessive–compulsive disorder. 2020, 663-674. DOI: 10.1016/b978-0-12-813866-3.00039-4.Peer-Reviewed Original ResearchObsessive-compulsive disorderEvidence-based treatmentsCognitive behavioral therapyTreatment-refractory obsessive-compulsive disorderSignificant hereditary componentRepetitive transcranial magnetic stimulationTranscranial magnetic stimulationBrain stimulantBehavioral therapyMagnetic stimulationCortico-striatoSelective serotonin reuptake inhibitorsPharmacological treatment strategiesFirst-line treatmentSerotonin reuptake inhibitorsAntipsychotic augmentationGenetic risk factorsReuptake inhibitorsDisordersRisk factorsTreatment strategiesAnimal studiesNeuroimagingModulating agentsHereditary component
2019
Meta-analysis of placebo group dropout in adult antidepressant trials
Li F, Nasir M, Olten B, Bloch MH. Meta-analysis of placebo group dropout in adult antidepressant trials. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2019, 98: 109777. PMID: 31697973, DOI: 10.1016/j.pnpbp.2019.109777.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderPlacebo leadAntidepressant trialsDiagnostic indicationsPlacebo-controlled trialStratified subgroup analysisBaseline illness severityMore study visitsDropout rateOverall dropout rateFreeman-Tukey transformationLonger trial durationEarlier publication yearPlacebo groupIllness severitySubgroup analysisDepressive disorderStudy visitMeta-AnalysisTrial durationAnxiety disordersTrialsEfficiency of trialsSubject burdenDisorders
2018
Supplementation with polyunsaturated fatty acids (PUFAs) in the management of attention deficit hyperactivity disorder (ADHD)
Banaschewski T, Belsham B, Bloch MH, Ferrin M, Johnson M, Kustow J, Robinson S, Zuddas A. Supplementation with polyunsaturated fatty acids (PUFAs) in the management of attention deficit hyperactivity disorder (ADHD). Nutrition And Health 2018, 24: 279-284. PMID: 29921155, PMCID: PMC6291899, DOI: 10.1177/0260106018772170.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderPUFA supplementationDeficit hyperactivity disorderManagement of ADHDFurther high-quality researchHyperactivity disorderPossible side effectsSmall beneficial effectRobust evidence baseChild attention-deficit hyperactivity disorderFatty acidsFrontline treatmentHigh-quality researchCurrent evidenceSide effectsPsychosocial interventionsTreatment approachesPanel consensusPatientsBeneficial effectsEvidence baseSupplementationInternational expertsDisordersAdults
2017
Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial
Taylor JH, Landeros-Weisenberger A, Coughlin C, Mulqueen J, Johnson JA, Gabriel D, Reed MO, Jakubovski E, Bloch MH. Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial. Neuropsychopharmacology 2017, 43: 325-333. PMID: 28849779, PMCID: PMC5729569, DOI: 10.1038/npp.2017.194.Peer-Reviewed Original ResearchConceptsLiebowitz Social Anxiety ScaleSocial anxiety disorderAnxiety disordersSocial Anxiety ScaleSelf-reported anxietySocial phobia symptomsRatings of anxietyPotent N-methyl-d-aspartate receptor antagonistPhobia symptomsAnxiety symptomsAnxiety ScaleImpact of ketamineInitial evidenceAnxietyTreatment respondersVAS anxietyPlacebo-controlled crossover trialRatingsDisordersLinear mixed modelsPrior studiesConcept trialInadequate symptom reliefRandom orderMixed modelsIntranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder
Adams TG, Bloch MH, Pittenger C. Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder. Journal Of Clinical Psychopharmacology 2017, 37: 269-271. PMID: 28121735, PMCID: PMC5321820, DOI: 10.1097/jcp.0000000000000659.Peer-Reviewed Original Research
2015
Family accommodation in obsessive-compulsive and anxiety disorders: a five-year update
Lebowitz ER, Panza KE, Bloch MH. Family accommodation in obsessive-compulsive and anxiety disorders: a five-year update. Expert Review Of Neurotherapeutics 2015, 16: 45-53. PMID: 26613396, PMCID: PMC4895189, DOI: 10.1586/14737175.2016.1126181.Peer-Reviewed Original ResearchConceptsFamily accommodationObsessive-compulsive disorderAnxiety disordersNeurobiological underpinningsSevere psychopathologySynthesis of findingsPsychiatric disordersDisordersPsychopathologyMain findingsDistressAccommodationFindingsUnderpinningsEnglish language papersFive-Year UpdatePsycINFOTherapeutic goalsIndividualsLanguage papersResearchAnxiety Disorder-Specific Predictors of Treatment Outcome in the Coordinated Anxiety Learning and Management (CALM) Trial
Jakubovski E, Bloch MH. Anxiety Disorder-Specific Predictors of Treatment Outcome in the Coordinated Anxiety Learning and Management (CALM) Trial. Psychiatric Quarterly 2015, 87: 445-464. PMID: 26563229, DOI: 10.1007/s11126-015-9399-6.Peer-Reviewed Original ResearchConceptsSocial anxiety disorderAnxiety disordersCoordinated Anxiety LearningAnxiety LearningPost-traumatic stress disorderSelf-efficacy expectanciesPositive treatment expectanciesGeneralized anxiety disorderTreatment outcomesStress disorderTreatment expectanciesSpecific treatment needsSocial supportPanic disorderDisordersLearningSocioeconomic statusPredictorsTic disorders
Leckman J, Bloch M. Tic disorders. 2015, 757-773. DOI: 10.1002/9781118381953.ch56.Peer-Reviewed Original ResearchPsychological processesCognitive-behavioral treatmentTourette syndromeEmotional processingCourse of developmentNeural mechanismsInhibitory controlBehavioral treatmentFirst-line interventionPathogenesis of TSEnvironmental influencesPathways of careTic disordersDelivery of careMotor regulationSensorimotor gatingTherapeutic algorithmClinical presentationDisordersRelated disordersTreatment trialsClinical expressionOrphan disorderExperienced cliniciansPathogenesisChapter 106 Obsessive–Compulsive Disorder
Bloch M, Lennington J, Szuhay G, Lombroso P. Chapter 106 Obsessive–Compulsive Disorder. 2015, 1301-1310. DOI: 10.1016/b978-0-12-410529-4.00106-6.Peer-Reviewed Original ResearchObsessive-compulsive disorderEvidence-based treatmentsTreatment-refractory obsessive-compulsive disorderSignificant hereditary componentRepetitive transcranial magnetic stimulationTranscranial magnetic stimulationThalamo-cortical circuitsMagnetic stimulationCortico-striatoSelective serotonin reuptake inhibitorsPharmacological treatment strategiesSerotonin reuptake inhibitorsAntipsychotic augmentationGenetic risk factorsReuptake inhibitorsDisordersRisk factorsTreatment strategiesAnimal studiesModulating agentsNeuroimagingHereditary componentCompulsionDeep brainObsessionChapter 107 Tourette Syndrome
Lennington J, Bloch M, Scahill L, Szuhay G, Lombroso P, Vaccarino F. Chapter 107 Tourette Syndrome. 2015, 1311-1320. DOI: 10.1016/b978-0-12-410529-4.00107-8.ChaptersTourette syndromeThalamic-cortical circuitryChildhood-onset neuropsychiatric disorderBasal ganglia circuitryStriatal interneuronsAmeliorate symptomsBasal gangliaPharmacological strategiesVocal ticsAnimal modelsPostmortem tissueNeuropsychiatric disordersSyndromeContemporary treatmentHeterogeneous disorderLarge genome-wide association studiesRecent screeningDysfunctionPotential target sitesStereotypic behaviorDisordersGenome-wide association studiesAssociation studiesChemical disruptionDopaminergic
2014
Pharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger C, Bloch MH. Pharmacological Treatment of Obsessive-Compulsive Disorder. Psychiatric Clinics Of North America 2014, 37: 375-391. PMID: 25150568, PMCID: PMC4143776, DOI: 10.1016/j.psc.2014.05.006.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderPharmacological treatmentLow-dose neuroleptic medicationsSelective serotonin reuptake inhibitorsProfound clinical challengeSecond-line treatmentSerotonin reuptake inhibitorsSignificant symptomatic reliefTricyclic clomipramineAppropriate pharmacotherapyNeuroleptic medicationReuptake inhibitorsSubstantial morbiditySymptomatic reliefAvailable treatmentsClinical challengeHigh dosesOCD refractoryTreatmentDisordersMedicationsMorbidityPharmacotherapyPatientsClomipramineA meta-analysis of computerized cognitive-behavioral therapy for the treatment of DSM-5 anxiety disorders.
Adelman CB, Panza KE, Bartley CA, Bontempo A, Bloch MH. A meta-analysis of computerized cognitive-behavioral therapy for the treatment of DSM-5 anxiety disorders. The Journal Of Clinical Psychiatry 2014, 75: e695-704. PMID: 25093485, DOI: 10.4088/jcp.13r08894.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyPerson cognitive-behavioural therapyComputerized cognitive behavioral therapyAnxiety disordersComputerized CBTNon-PTSD anxiety disordersCompletion of treatmentTreatment gainsStandardized mean differenceDSM-5 anxiety disordersGreater symptom reductionWait-list controlSpecific anxiety disordersFixed-effects modelClinical outcomesClinical comorbiditiesEfficacious interventionsSymptom reductionReal-world settingGreater efficacyMeta-AnalysisCBT treatmentMean differenceDisordersAnxiety symptoms